Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(1S,3S)-3-acetyl-3,5,10-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside | - |
Homo sapiens | |
(3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,5a,6,11,11a-octahydrotetracen-1-yl 3-(2-cyanopiperidin-1-yl)-2,3,6-trideoxy-alpha-D-glycero-hexopyranoside | - |
Homo sapiens | |
(3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,5a,6,11,11a-octahydrotetracen-1-yl-2,6-dideoxy-beta-L-threo-hexopyranoside | - |
Homo sapiens | |
(3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,5a,6,11,11a-octahydrotetracen-1-yl-3-amino-2,3,6-trideoxy-alpha-D-erythro-hexopyranoside | - |
Homo sapiens | |
(3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,5a,6,11,11a-octahydrotetracen-1-yl-3-amino-2,3,6-trideoxy-beta-L-threo-hexopyranoside | - |
Homo sapiens | |
(3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,5a,6,11,11a-octahydrotetracen-1-yl-4-amino-2,4,6-trideoxy-alpha-D-erythro-hexopyranoside | - |
Homo sapiens | |
(3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-6,11-dioxo-1,2,3,4,5a,6,11,11a-octahydrotetracen-1-yl-2,6-dideoxy-beta-L-threo-hexopyranoside | - |
Homo sapiens | |
(3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-6,11-dioxo-1,2,3,4,5a,6,11,11a-octahydrotetracen-1-yl-3-amino-2,3,6-trideoxy-alpha-D-erythro-hexopyranoside | - |
Homo sapiens | |
(3S)-3-acetyl-3,5,10-trihydroxy-6,11-dioxo-1,2,3,4,5a,6,11,11a-octahydrotetracen-1-yl-3-amino-2,3,6-trideoxy-alpha-D-erythro-hexopyranoside | - |
Homo sapiens | |
(3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,5a,6,11,11a-octahydrotetracen-1-yl-3,4-diamino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranoside | - |
Homo sapiens | |
(3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,5a,6,11,11a-octahydrotetracen-1-yl-3-amino-2,3,6-trideoxy-alpha-D-erythro-hexopyranoside | - |
Homo sapiens | |
(3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,5a,6,11,11a-octahydrotetracen-1-yl-4-amino-2,4,6-trideoxy-alpha-D-threo-hexopyranoside | - |
Homo sapiens | |
(3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,5a,6,11,11a-octahydrotetracen-1-yl-2,6-dideoxy-beta-L-threo-hexopyranoside | - |
Homo sapiens | |
(3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,5a,6,11,11a-octahydrotetracen-1-yl-3-amino-2,3,6-trideoxy-alpha-D-erythro-hexopyranoside | - |
Homo sapiens | |
(8S)-10-[[(2R,4R)-4-amino-6-methyltetrahydro-2H-pyran-2-yl]oxy]-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5a,7,8,9,10,11a-hexahydrotetracene-5,12-dione | - |
Homo sapiens | |
(8S)-10-[[(2S,4S,5S)-4-amino-5-iodo-6-methyltetrahydro-2H-pyran-2-yl]oxy]-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5a,7,8,9,10,11a-hexahydrotetracene-5,12-dione | - |
Homo sapiens | |
(8S)-8-acetyl-10-[[(2R,4R)-4-amino-6-methyltetrahydro-2H-pyran-2-yl]oxy]-6,8,11-trihydroxy-1-methoxy-5a,7,8,9,10,11a-hexahydrotetracene-5,12-dione | - |
Homo sapiens | |
(9S)-7-[[(2R,4R)-4-amino-6-methyltetrahydro-2H-pyran-2-yl]oxy]-6,9,11-trihydroxy-9-(hydroxyacetyl)-5a,7,8,9,10,11a-hexahydrotetracene-5,12-dione | - |
Homo sapiens | |
(9S)-9-acetyl-7-[[(2S,5R)-5-amino-6-methyltetrahydro-2H-pyran-2-yl]oxy]-6,9,11-trihydroxy-5a,7,8,9,10,11a-hexahydrotetracene-5,12-dione | - |
Homo sapiens | |
12-(6-piperidin-1-ylhexyl)-7,12-dihydro-6H-[1]benzothiepino[5,4-b]indole | - |
Homo sapiens | |
4-demethyl-6-deoxydaunorubicin | - |
Homo sapiens | |
aleuritolic acid | - |
Homo sapiens | |
chelerythrine chloride | low active inhibitor | Homo sapiens | |
doxorubicin | an antitumor drug, potent inhibitor | Homo sapiens | |
Fagaronine chloride | most potent inhibitor | Homo sapiens | |
Fulvoplumierin | - |
Homo sapiens | |
additional information | not inhibited by apigenin, betulinic acid, (-)-catechin, chloroquine, chelidonine, N-demethylfagaronine, berberine, coptisine chloride, tetrahydroberberine, and tertahydropalmatine | Homo sapiens | |
morin | - |
Homo sapiens | |
myricetin | - |
Homo sapiens | |
N-[5-([5-[(3-amino-3-iminopropyl)carbamoyl]-1-methyl-1H-pyrrol-3-yl]carbamoyl)-1-methyl-1H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1H-pyrrole-2-carboxamide hydrochloride | distamycin A | Homo sapiens | |
N-[5-([5-[(3-amino-3-iminopropyl)carbamoyl]-1-methyl-1H-pyrrol-3-yl]carbamoyl)-1-methyl-1H-pyrrol-3-yl]-4-[([4-[bis(2-chloroethyl)amino]phenyl]carbonyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride | FCE-24517 | Homo sapiens | |
Nitidine chloride | most potent inhibitor | Homo sapiens | |
oleanolic acid | - |
Homo sapiens | |
Protolichesterinic acid | - |
Homo sapiens | |
sanguinarine | low active inhibitor | Homo sapiens | |
Swertifrancheside | flavonoxanthone glucoside | Homo sapiens | |
ursolic acid | - |
Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
ATP + (deoxyribonucleotide)n + (deoxyribonucleotide)m | DNA ligase I ligates Okazaki fragments during lagging strand DNA replication events | Homo sapiens | AMP + diphosphate + (deoxyribonucleotide)m+n | - |
? |
Synonyms | Comment | Organism |
---|---|---|
DNA ligase I | - |
Homo sapiens |
Cofactor | Comment | Organism | Structure |
---|---|---|---|
ATP | - |
Homo sapiens |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.027 | - |
- |
Homo sapiens | Fagaronine chloride | |
0.069 | - |
- |
Homo sapiens | Nitidine chloride | |
0.091 | - |
- |
Homo sapiens | myricetin | |
0.105 | - |
- |
Homo sapiens | Swertifrancheside | |
0.205 | - |
- |
Homo sapiens | aleuritolic acid | |
0.216 | - |
- |
Homo sapiens | ursolic acid | |
0.216 | - |
- |
Homo sapiens | oleanolic acid | |
0.226 | - |
- |
Homo sapiens | chelerythrine chloride | |
0.236 | - |
- |
Homo sapiens | morin | |
0.322 | - |
- |
Homo sapiens | sanguinarine | |
0.357 | - |
- |
Homo sapiens | Fulvoplumierin | |
0.387 | - |
- |
Homo sapiens | Protolichesterinic acid |